Ovarian cancer trials in Belgium
45 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 Nov 2026. Ask the study team whether a trial fits you.
Phase 3RecruitingTrial-stage medicine
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
- Where
- Brussels, Edegem, Leuven
- Age
- 18 years and over
- People
- 420 worldwide
- Run by
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
See details and how to joinNCT07546500Registry updated 2026-11-09
No phaseRecruitingResearch participation
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
- Where
- Edegem
- Age
- 18 years and over
- People
- 730
- Run by
- Universiteit Antwerpen
See details and how to joinNCT07902375Registry updated 2026-11-06
Phase 3RecruitingTrial-stage medicine
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Where
- Anderlecht, Bruges, Edegem, Ghent, Leuven
- Age
- 18 years and over
- People
- 1,630 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07213804EU 2025-522255-25-00Registry updated 2026-11-04
Phase 1/2RecruitingTrial-stage medicine
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- Where
- Gent, Kortrijk, Leuven, Mechelen, Sint-Lambrechts-Woluwe
- Age
- 18 years and over
- People
- 334 worldwide
- Run by
- Gilead Sciences
See details and how to joinNCT06303505EU 2024-511074-80-01Registry updated 2026-11-03
Phase 3RecruitingTrial-stage medicine
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
- Where
- Edegem, Gent, Leuven, Liège, Namur
- Age
- 18 years and over
- People
- 270 worldwide
- Run by
- Verastem, Inc.
See details and how to joinNCT06072781EU 2023-508204-38-00Registry updated 2026-11-02
Phase 3RecruitingResearch participation
Phase 3 Study of Azenosertib Versus Chemotherapy in Platinum-Resistant Ovarian Cancers Positive for Cyclin E1 Protein Expression
- Where
- Brussels, Leuven
- Age
- 18 years and over
- People
- 197 worldwide
- Run by
- K-Group Beta Inc.
See details and how to join2025-524641-27-00EU 2025-524641-27-00Registry updated 2026-10-30
Phase 2RecruitingTrial-stage medicine
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Where
- Leuven, Sint-Lambrechts-Woluwe
- Age
- 18 years and over
- People
- 310 worldwide
- Run by
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
See details and how to joinNCT05128825EU 2022-502983-19-00Registry updated 2026-10-30
Phase 3RecruitingTrial-stage medicine
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Where
- Gent, Leuven, Liège, Namur, Sint-Lambrechts-Woluwe
- Age
- 18 years and over
- People
- 582 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06819007EU 2024-516982-35-00Registry updated 2026-10-28
Phase 2RecruitingTrial-stage medicine
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Brussels, Edegem, Ghent, Jette, Leuven
- Age
- 18 years and over
- People
- 740 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478EU 2023-507641-29-00Registry updated 2026-10-26
Phase 1/2RecruitingTrial-stage medicine
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Charleroi, Gent, Leuven, Liège, Sint-Lambrechts-Woluwe
- Age
- 18 years and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064EU 2023-509632-26-00Registry updated 2026-10-26
Phase 2RecruitingTrial-stage medicine
A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy
- Where
- Gent, Hasselt, Leuven, Sint-Lambrechts-Woluwe
- Age
- 18 years and over
- People
- 640 worldwide
- Run by
- North Eastern German Society of Gynaecological Oncology
See details and how to joinNCT05460000EU 2022-502559-69-01Registry updated 2026-10-23
No phaseNot yet recruitingResearch participation
AI Analysis of CT Scans to Classify Ovarian Tumours as Benign, Borderline or Malignant Before Surgery
- Where
- Ghent
- Age
- 18 years and over
- People
- 1,300 worldwide
- Run by
- Catharina Ziekenhuis Eindhoven
See details and how to joinNCT07883551Registry updated 2026-10-20
Phase 3RecruitingTrial-stage medicine
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Where
- Anderlecht, Gent, Kortrijk, Leuven, Sint-Lambrechts-Woluwe
- Age
- 18 years and over
- People
- 466 worldwide
- Run by
- Incyte Corporation
See details and how to joinNCT07214779EU 2025-522748-42-00Registry updated 2026-10-15
Phase 1/2RecruitingTrial-stage medicine
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Where
- Anderlecht, Leuven
- Age
- 18 years and over
- People
- 460 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05123482EU 2022-502759-70-01Registry updated 2026-10-13
Phase 3RecruitingTrial-stage medicine
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Where
- Edegem, Gent, Leuven, Liège, Namur
- Age
- 18 years and over
- People
- 770 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06824467EU 2023-508015-23-00Registry updated 2026-10-13
Phase 2RecruitingTrial-stage medicine
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
- Where
- Gent, Leuven, Liège, Namur, Sint-Lambrechts-Woluwe
- Age
- 18 years and over
- People
- 400 worldwide
- Run by
- AbbVie
See details and how to joinNCT07059845EU 2025-521606-18-00Registry updated 2026-10-13
Phase 3RecruitingTrial-stage medicine
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- Where
- Anderlecht, Charleroi, Gent, Leuven
- Age
- 18 years and over
- People
- 900 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07318558EU 2023-508047-40-00Registry updated 2026-10-13
Phase 1RecruitingTrial-stage medicine
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
- Where
- Kortrijk, Leuven, Liège
- Age
- 15 years and over
- People
- 282 worldwide
- Run by
- Xencor, Inc.
See details and how to joinNCT06276491Registry updated 2026-10-09
Phase 3RecruitingTrial-stage medicine
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
- Where
- Gent, Hasselt, Leuven, Libramont-Chevigny, Liège, Roeselare, Sint-Lambrechts-Woluwe, Sint-Niklaas
- Age
- 18 years and over
- People
- 544 worldwide
- Run by
- Genmab
See details and how to joinNCT07225270EU 2025-522167-15-00Registry updated 2026-10-06
Phase 1/2RecruitingTrial-stage medicine
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- Where
- Edegem, Gerpinnes, Leuven
- Age
- 18 years and over
- People
- 890 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT03564340EU 2024-510783-23-00Registry updated 2026-09-25
Phase 1/2RecruitingTrial-stage medicine
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
- Where
- Leuven
- Age
- 18 years and over
- People
- 612 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT04590326EU 2022-501904-83-00Registry updated 2026-09-24
Phase 2RecruitingTrial-stage medicine
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Where
- Anderlecht, Kortrijk, Leuven, Liège, Sint-Lambrechts-Woluwe
- Age
- 18 years to 99 years
- People
- 160 worldwide
- Run by
- Incyte Corporation
See details and how to joinNCT07023627EU 2025-521513-14-00Registry updated 2026-09-15
Phase 1/2RecruitingTrial-stage medicine
Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer
- Where
- Gent, Leuven, Liège, Sint-Lambrechts-Woluwe
- Age
- 18 years and over
- People
- 72 worldwide
- Run by
- Gilead Sciences
See details and how to joinNCT07736937EU 2025-524691-33-00Registry updated 2026-09-01
Phase 1RecruitingTrial-stage medicine
A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
- Where
- Sint-Lambrechts-Woluwe
- Age
- 18 years and over
- People
- 187 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07306559EU 2025-522913-45-00Registry updated 2026-08-21
Phase 1/2RecruitingTrial-stage medicine
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
- Where
- Antwerp, Brussels, Liège
- Age
- 18 years and over
- People
- 230 worldwide
- Run by
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
See details and how to joinNCT05985655Registry updated 2026-08-13
All Ovarian cancer trials and the map
This page is not medical advice. Talk to your doctor before contacting a trial.